Wave Life Sciences Ltd. — Director's Dealing 2018

Feb 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2018-02-15

Reporting Person: Panzara Michael A. (Franchise Lead, Neurology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-15	Ordinary Shares	M	18750	$21.69	Acquired	58486	Direct
2018-02-15	Ordinary Shares	S	18750	$50.00	Disposed	39736	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-15	Share Option (right to buy)	$21.69	M	18750	Disposed	2026-07-11	Ordinary Shares (18750)	Direct

Footnotes

F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.

F2: The share option represented a right to purchase a total of 150,000 ordinary shares, 25% of which became exercisable on July 11, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.